Therapeutic potential of natural products against atherosclerosis: Targeting on gut microbiota.
Therapeutic potential of natural products against atherosclerosis: Targeting on gut microbiota.
复制标题
DOI：
10.1016/j.phrs.2020.105362
复制
发表时间：
2020-12
影响因子：
9.3
通讯作者：
Xin Zhao;Patrick Kwabena Oduro;W. Tong;Yuefei Wang;Xiumei Gao;Qilong Wang
中科院分区：
文献类型：
--
作者：
Xin Zhao;Patrick Kwabena Oduro;W. Tong;Yuefei Wang;Xiumei Gao;Qilong Wang
肠道微生物群（GM）已成为维持人类健康和影响病理结果的必要和不可或缺的因素。宏基因组学和代谢组学表征进一步加深了对肠道宏基因组学的理解，揭示了特定转基因社区成员的偏离和转基因依赖代谢物的失衡是代谢性或心血管疾病（cvd）的主因。利用益生元和益生菌等营养补充品恢复转基因生态系统，可以相对降低心血管疾病的发病率和总死亡率。在动脉粥样硬化中，共生和致病肠道微生物与动脉粥样硬化事件相关。转基因依赖的代谢物-三甲胺n -氧化物和短链脂肪酸以相反的模式调节动脉粥样硬化相关的代谢过程，从而影响动脉粥样硬化的结局。因此，GM可能是动脉粥样硬化的潜在治疗靶点。在致动脉粥样硬化动物模型中，具有心脏保护特性的天然产物可以通过激活更健康的转基因物种型和消除致动脉粥样硬化代谢物来调节转基因生态系统，为临床治疗铺平了未来的研究道路。
Gut microbiota (GM) has emerged as an essential and integral factor for maintaining human health and affecting pathological outcomes. Metagenomics and metabolomics characterization have furthered gut metagenome’s understanding and unveiled that deviation of specific GM community members and GM-dependent metabolites imbalance orchestrate metabolic or cardiovascular diseases (CVDs). Restoring GM ecosystem with nutraceutical supplements keenly prebiotics and probiotics relatively decreases CVDs incidence and overall mortality. In Atherosclerosis, commensal and pathogenic gut microbes correlate with atherogenesis events. GM-dependent metabolites-trimethylamine N-oxide and short-chain fatty acids regulate atherosclerosis-related metabolic processes in opposite patterns to affect atherosclerosis outcomes. Therefore, GM might be a potential therapeutic target for atherosclerosis. In atherogenic animal models, natural products with cardioprotective properties could modulate the GM ecosystem by revitalizing healthier GM phylotypes and abrogating proatherogenic metabolites, paving future research paths for clinical therapeutics.